Form 8-K - Current report:
SEC Accession No. 0001104659-21-071258
Filing Date
2021-05-24
Accepted
2021-05-24 16:41:38
Documents
9
Period of Report
2021-05-21
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2117347d1_8k.htm 8-K 26350
2 EXHIBIT 1.1 tm2117347d1_ex1-1.htm EX-1.1 273794
3 EXHIBIT 5.1 tm2117347d1_ex5-1.htm EX-5.1 15398
4 EXHIBIT 99.1 tm2117347d1_ex99-1.htm EX-99.1 10444
5 EXHIBIT 99.2 tm2117347d1_ex99-2.htm EX-99.2 12615
6 GRAPHIC tm2117347d1img_002.jpg GRAPHIC 3964
7 GRAPHIC tm2117347d1_ex5-1img003.jpg GRAPHIC 2345
8 GRAPHIC tm2117347d1_ex99-1img001.jpg GRAPHIC 13759
9 GRAPHIC tm2117347d1_ex99-2img01.jpg GRAPHIC 3646
  Complete submission text file 0001104659-21-071258.txt   373152
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39202 | Film No.: 21955569
SIC: 2834 Pharmaceutical Preparations